Malin : > Malin Corporation plc 2023 Information Statements

MALIN CORPORATION PLC

EIN: 98-1313350

PASSIVE FOREIGN INVESTMENT COMPANY ("PFIC") ANNUAL INFORMATION

STATEMENT

FOR TAXABLE YEAR-ENDED DECEMBER 31, 2023

PFIC Name: Malin Corporation plc

PFIC Address: The Lennox Building, Richmond Street South, Dublin 2, Ireland

EIN: 98-1313350

REFERENCE ID NUMBER: MCORP

1. This PFIC Annual Information Statement applies to the taxable year of Malin Corporation plc beginning on January 1, 2023 and ending on December 31, 2023 ("Tax Year 2023"). It is being provided to you pursuant to Treas. Reg. §1.1295- 1(g)(1).
2. Malin Corporation plc has the following ordinary earnings and net capital gain for Tax Year 2023:

1. The amount of cash and fair market value ("FMV") of other property distributed or deemed distributed by Malin Corporation plc during Tax Year 2023 is as follows:

1. Malin Corporation plc will permit the Shareholder to inspect and copy the PFIC's permanent books of account, records, and such other documents as may be maintained by the PFIC that are necessary to establish that the PFIC's ordinary earnings and net capital gain, as provided in §1293(e), are computed in accordance with U.S. income tax principles.
   Andrea Stafford
   Head of Finance, Malin Corporation plc 10 April, 2024

Malin Corporation plc, The Lennox Building, Richmond Street South, Dublin 2, Ireland

T: +353 (0)1 901 5700 | F: +353 (0)1 901 5701

Directors: L. Daniel (Chairman), J.M. Cosséry (Belgium), R. Mareel (Belgium), F. Dunlevy, C. Pedrick (UK), K. Drejer (Denmark Registered in Ireland, No: 554442

NIDUS LABORATORIES IRELAND LTD

EIN: N/A

PASSIVE FOREIGN INVESTMENT COMPANY ("PFIC") ANNUAL INFORMATION

STATEMENT

FOR TAXABLE YEAR-ENDED DECEMBER 31, 2023

PFIC Name: Nidus Laboratories Ireland Ltd

PFIC Address: The Lennox Building, Richmond Street South, Dublin 2, Ireland

EIN: N/A

REFERENCE ID NUMBER: NLIREL

1. % HELD BY MALIN CORPORATION PLC: 100%

2. This PFIC Annual Information Statement applies to the taxable year of Nidus Laboratories Ireland Ltd beginning on January 1, 2023 and ending on December 31, 2023 ("Tax Year 2023"). It is being provided to you pursuant to Treas. Reg. §1.1295-1(g)(1).
3. Nidus Laboratories Ireland Ltd has the following ordinary earnings and net capital gain for Tax Year 2023:
   Ordinary Earnings: NONE

1. The amount of cash and fair market value ("FMV") of other property distributed or deemed distributed by Nidus Laboratories Ireland Ltd during Tax Year 2023 is as follows:

1. Nidus Laboratories Ireland Ltd will permit the Shareholder to inspect and copy the PFIC's permanent books of account, records, and such other documents as may be maintained by the PFIC that are necessary to establish that the PFIC's ordinary earnings and net capital gain, as provided in §1293(e), are computed in accordance with U.S. income tax principles.
   Andrea Stafford
   Head of Finance, Malin Corporation plc 10 April, 2024

2

WAVEBREAK THERAPEUTICS LIMITED (FKA WREN THERAPEUTICS LIMITED)

EIN: N/A

PASSIVE FOREIGN INVESTMENT COMPANY ("PFIC") ANNUAL INFORMATION

STATEMENT

FOR TAXABLE YEAR-ENDED DECEMBER 31, 2023

PFIC Name: WaveBreak Therapeutics Limited (fka Wren Therapeutics Limited)

PFIC Address: Clarendon House, Clarendon Road, Cambridge, UK CB28FH

EIN: N/A

REFERENCE ID NUMBER: WREN

1. % HELD BY MALIN CORPORATION PLC: 10.5%

2. This PFIC Annual Information Statement applies to the taxable year of WaveBreak Therapeutics Limited (fka Wren Therapeutics Limited) beginning on January 1, 2023 and ending on December 31, 2023 ("Tax Year 2023"). It is being provided to you pursuant to Treas. Reg. §1.1295-1(g)(1).
3. WaveBreak Therapeutics Limited (fka Wren Therapeutics Limited) has the following ordinary earnings and net capital gain for Tax Year 2023:
   Ordinary Earnings: NONE

1. The amount of cash and fair market value ("FMV") of other property distributed or deemed distributed by WaveBreak Therapeutics Limited (fka Wren Therapeutics Limited) during Tax Year 2023 is as follows:

1. WaveBreak Therapeutics Limited (fka Wren Therapeutics Limited) will permit the Shareholder to inspect and copy the PFIC's permanent books of account, records, and such other documents as may be maintained by the PFIC that are necessary to establish that the PFIC's ordinary earnings and net capital gain, as provided in §1293(e), are computed in accordance with U.S. income tax principles.
   Andrea Stafford
   Head of Finance, Malin Corporation plc 10 April, 2024

3